Infographic: ranibizumab or bevacizumab treat & extend for neovascular age-related macular degeneration (AMD): LUCAS trial

被引：0
|
作者：
Barai, Ishani [1 ]
Sivaprasad, Sobha [1 ]
Henein, Christin [1 ]
机构：
[1] UCL, Inst Ophthalmol, London, England
来源：
EYE | 2025年 / 39卷 / SUPPL1期
关键词：
D O I：
10.1038/s41433-024-03339-z
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：129 / 131
页数：3
相关论文
共 50 条
  • [1] Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
    Berg, Karina
    Pedersen, Terje R.
    Sandvik, Leiv
    Bragadottir, Ragnheidur
    OPHTHALMOLOGY, 2015, 122 (01) : 146 - 152
  • [2] Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
    Chakravarthy, Usha
    Harding, Simon P.
    Rogers, Chris A.
    Downes, Susan M.
    Lotery, Andrew J.
    Wordsworth, Sarah
    Reeves, Barnaby C.
    OPHTHALMOLOGY, 2012, 119 (07)
  • [3] Ranibizumab treat and extend for neovascular age-related macular degeneration (AMD) - One-year outcomes
    Trivedi, Dipti
    Alfaqawi, Fadi
    Lip, Peck Lin
    Mushtaq, Bushra
    Chavan, Randhir
    EYE, 2018, 32 (11) : 20 - 23
  • [4] Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat and extend trial
    Hatz, Katja B.
    Pruente, Christian
    Binningen, Vistaklinik
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L., III
    OPHTHALMOLOGY, 2012, 119 (07) : 1388 - 1398
  • [6] A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
    Chin-Yee, David
    Eck, Thomas
    Fowler, Susan
    Hardi, Angela
    Apte, Rajendra S.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2016, 100 (07) : 914 - 917
  • [7] A Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to a Treat and Extend Protocol: 1-Year Results from the LUCAS Study
    Berg, Karina
    OPHTHALMOLOGICA, 2014, 232 : 18 - 19
  • [8] Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab
    Abdelfattah, Nizar S.
    Al-Sheikh, Mayss
    Pitetta, Sean
    Mousa, Ahmed
    Sadda, SriniVas R.
    Wykoff, Charles C.
    OPHTHALMOLOGY, 2017, 124 (02) : 215 - 223
  • [9] INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial
    Hatz, Katja
    Prunte, Christian
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (06): : 1185 - 1192
  • [10] Infographic: The port delivery system with ranibizumab for neovascular age-related macular degeneration: LADDER trial
    Barai, Ishani
    Sivaprasad, Sobha
    Henein, Christin
    EYE, 2025, 39 (SUPPL1) : 126 - 128
12345